永安药业(002365) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥218,568,021.59, representing a decrease of 21.73% compared to ¥279,265,466.80 in the same period last year[8] - Net profit attributable to shareholders was ¥4,943,479.06, down 27.17% from ¥6,787,546.94 year-on-year[8] - The net profit after deducting non-recurring gains and losses increased by 85.49% to ¥2,329,764.15 from ¥1,255,989.38 in the previous year[8] - Basic and diluted earnings per share decreased by 26.09% to ¥0.0170 from ¥0.0230 year-on-year[8] - Net profit decreased by 30.15% to ¥6,862,854.24, attributed to a reduction in total profit[16] - Total operating revenue for Q1 2020 was CNY 218,568,021.59, a decrease of 21.7% compared to CNY 279,265,466.80 in Q1 2019[49] - Net profit for Q1 2020 was CNY 6,862,854.24, representing a decline of 30.0% from CNY 9,824,787.28 in Q1 2019[50] - The total comprehensive income for Q1 2020 was CNY 7,272,708.31, down from CNY 12,210,262.59 in Q1 2019[51] Cash Flow and Liquidity - The net cash flow from operating activities improved by 32.61%, reaching -¥22,630,489.63 compared to -¥33,583,740.70 in the same period last year[8] - Cash and cash equivalents decreased by 33.05% to ¥78,555,180.59 due to reduced collections and increased investments[16] - The company reported a net cash increase of negative CNY 38,779,789.53, compared to a positive increase of CNY 81,030,422.50 in the prior year[59] - Total cash inflow from operating activities was CNY 118,385,171.25, a decline of 41.5% from CNY 202,356,148.37[60] - Total cash outflow from operating activities was CNY 115,351,973.39, down from CNY 216,566,195.78 in the previous period[60] - Investment cash inflow was CNY 223,900,877.40, a decrease of 34.0% compared to CNY 339,068,969.20 in the prior period[58] - Net cash flow from investment activities was negative CNY 20,304,689.70, contrasting with a positive CNY 116,460,262.44 in the previous year[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,872,960,719.31, a decrease of 1.83% from ¥1,907,848,550.84 at the end of the previous year[8] - Total liabilities amounted to CNY 251,135,078.84, with current liabilities at CNY 207,901,502.36 and non-current liabilities at CNY 43,233,576.48[65] - Current liabilities decreased from CNY 207,901,502.36 to CNY 141,470,966.46, a reduction of about 32%[41] - Non-current assets totaled CNY 1,126,234,782.76, down from CNY 1,150,809,120.06, reflecting a decrease of approximately 2.14%[40] - Total current assets amounted to ¥746,725,936.55, down from ¥757,039,430.78, reflecting a decrease of approximately 1.4%[38] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,145[12] - The largest shareholder, Chen Yong, holds 21.54% of the shares, totaling 63,468,000 shares[12] - The company has completed the first phase of share repurchase, acquiring 5,038,557 shares, representing 1.71% of the total share capital, with a total transaction amount of RMB 49,992,848.77[23] - The second phase of share repurchase began on September 18, 2019, with a total of 2,443,046 shares repurchased by December 31, 2019, accounting for 0.83% of the total share capital, totaling RMB 20,850,949.14[24] Research and Development - Research and development expenses decreased by 52.51% to ¥4,812,833.07 due to a significant reduction in R&D activities caused by the pandemic[16] - Research and development expenses decreased to CNY 4,812,833.07 in Q1 2020, a reduction of 52.5% compared to CNY 10,134,651.37 in Q1 2019[49] Government Support and Subsidies - The company received government subsidies amounting to ¥2,262,502.99 during the reporting period[9] - Other income for Q1 2020 was CNY 2,262,502.99, an increase from CNY 1,981,324.18 in Q1 2019[49] Compliance and Governance - The company has not engaged in derivative investments during the reporting period, ensuring a focus on core operations[31] - There were no violations regarding external guarantees during the reporting period, reflecting sound governance practices[32] - The company did not report any non-operating fund occupation by controlling shareholders or related parties, indicating a stable financial environment[33] - The company has fulfilled its commitments regarding information disclosure and equity incentive plans[25]